摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-amino-5-bromo-phenyl) cyclohexanol | 304854-03-3

中文名称
——
中文别名
——
英文名称
1-(2-amino-5-bromo-phenyl) cyclohexanol
英文别名
1-(2-Amino-5-bromo-phenyl)cyclohexanol;1-(2-amino-5-bromophenyl)cyclohexan-1-ol
1-(2-amino-5-bromo-phenyl) cyclohexanol化学式
CAS
304854-03-3
化学式
C12H16BrNO
mdl
——
分子量
270.169
InChiKey
APLKINOTQCGFDO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
    摘要:
    这项发明提供了具有以下一般结构的孕激素受体激动剂和拮抗剂的化合物:其中:R1和R2分别选择自H、CORA或NRBCORA,或者可选择取代的烷基、烯基、炔基、环烷基、芳基或杂环基;或者R1和R2融合形成:3到8成员的螺环烷基、烯基或杂环环;RA为H或可选择取代的烷基、芳基、烷氧基或氨基烷基;RB为H、C1至C3烷基或取代的C1至C3烷基;R3为H、OH、NH2、CORC或可选择取代的烷基、烯基或炔基;RC为H或可选择取代的烷基、芳基、烷氧基或氨基烷基;R4为H、卤素、CN、NO2或可选择取代的烷基、炔基、烷氧基、氨基或氨基烷基;R5为可选择取代的苯或含有1、2或3个来自O、S、SO、SO2或NR6的杂原子的五元或六元环;R6为H或C1至C3烷基;G1为O、NR7或CR7R8;G2为CO、CS或CR7R8;条件是当G1为O时,G2为CR7R8,且G1和G2不能同时为CR7R8;R7和R8为H或可选择取代的烷基、芳基或杂环基;或其药用盐,以及在哺乳动物中使用这些化合物作为孕激素受体激动剂或拮抗剂的方法。
    公开号:
    US06358948B1
  • 作为产物:
    参考文献:
    名称:
    Cyclothiocarbamate derivatives as progesterone receptor modulators
    摘要:
    本发明提供了使用具有孕激素受体激动剂特性的化合物进行避孕和单独或与雌激素受体激动剂或孕激素受体拮抗剂联合治疗孕激素相关疾病的方法。这些化合物具有以下结构:其中R1、R2、R3、R4、R5和Q1在此定义。
    公开号:
    US07569564B2
点击查看最新优质反应信息

文献信息

  • Cyclocarbamate derivatives as progesterone receptor modulators
    申请人:——
    公开号:US20020049204A1
    公开(公告)日:2002-04-25
    This invention provides compounds of Formula (I): 1 wherein R 1 and R 2 may be single substituents or fused to form spirocyclic or hetero-spirocyclic rings; R 3 is H, OH, NH 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, C 3 to C 6 alkenyl, substituted C 1 to C 6 alkenyl, alkynyl, or substituted alkynyl, COR C ; R C is H, C 1 to C 3 alkyl, substituted C 1 to C 3 alkyl, aryl, substituted aryl, C 1 to C 3 alkoxy, substituted C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, or substituted C 1 to C 3 aminoalkyl; R 4 is H, halogen, CN, NO 2 , C 1 to C 6 alkyl, substituted C 1 to C 6 alkyl, alkynyl, or substituted alkynyl, C 1 to C 6 alkoxy, substituted C 1 to C 6 alkoxy, amino, C 1 to C 6 aminoalkyl, or substituted C 1 to C 6 aminoalkyl; and R 5 is selected from a trisubstituted benzene ring of a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO 2 or NR 6 and containing one or two independent substituents from the group including H, halogen, CN, NO 2 , amino, and C 1 to C 3 alky, C 1 to C 3 alkoxy, C 1 to C 3 aminoalkyl, COR F , or NR G COR F ; or pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods using the compounds as antagonists of the progesterone receptor.
    这项发明提供了Formula (I)的化合物: 其中R1和R2可以是单个取代基或融合形成螺环或杂环螺环;R3为H、OH、NH2、C1到C6烷基、取代的C1到C6烷基、C3到C6烯基、取代的C1到C6烯基、炔基或取代的炔基、CORC;RC为H、C1到C3烷基、取代的C1到C3烷基、芳基、取代的芳基、C1到C3烷氧基、取代的C1到C3烷氧基、C1到C3基烷基或取代的C1到C3基烷基; R4为H、卤素、CN、NO2、C1到C6烷基、取代的C1到C6烷基、炔基或取代的炔基、C1到C6烷氧基、取代的C1到C6烷氧基、基、C1到C6基烷基或取代的C1到C6基烷基;R5从包括O、S、SO、SO2或NR6的1、2或3个杂原子的五元或六元环的三取代苯环中选择,并含有来自包括H、卤素、CN、 、基和C1到C3烷基、C1到C3烷氧基、C1到C3基烷基、CORF或NRGCORF的一个或两个独立取代基;或其药学上可接受的盐,以及将这些化合物用作孕激素受体拮抗剂的药物组合物和方法。
  • 7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
    申请人:Zhang Puwen
    公开号:US20050215539A1
    公开(公告)日:2005-09-29
    This invention provides progesterone receptor modulators having the structure: wherein R 1 to R 7 , X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    这项发明提供了具有以下结构的孕激素受体调节剂:其中R1至R7、X和Q如规范中所定义;或其药用可接受盐。
  • 1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5′-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators
    作者:Jeffrey C. Kern、Eugene A. Terefenko、Andrew Fensome、Ray Unwalla、Jay Wrobel、Jeffrey Cohen、Yuan Zhu、Thomas J. Berrodin、Matthew R. Yudt、Richard C. Winneker、Zhiming Zhang、Puwen Zhang
    DOI:10.1016/j.bmcl.2008.08.015
    日期:2008.9
    A series of novel 7-(5'-cyanopyrrol-2-yl) substituted benzo[1,4]oxazepin-2-ones were prepared and tested for their progesterone receptor (PR) agonist or antagonist activity in the alkaline phosphatase assay using the human T47D breast carcinoma cell line. Both PR agonists and antagonists were achieved with an appropriate choice of 5-substitution. Several analogs were potent PR agonists (e.g., 12 and
    制备了一系列新型的7-(5'-吡咯-2-基)取代的苯并[1,4]恶唑啉-2-酮,并使用人T47D乳腺癌细胞系。PR激动剂和拮抗剂均可通过选择5取代来实现。几种类似物是有效的PR激动剂(例如12和13)或PR拮抗剂(例如18),对其他类固醇受体具有良好的选择性。
  • SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
    申请人:Commons Thomas Joseph
    公开号:US20090197878A1
    公开(公告)日:2009-08-06
    Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R 1 -R 6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional bleeding, polycystic ovary syndrome, and menopause related symptoms; methods of contraception; methods of providing hormone replacement therapy; methods of stimulating food intake; methods of synchronizing estrus; and methods of treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder by administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (I).
    提供式(I)的化合物,或其药学上可接受的盐,其中R1-R6和X在此处有定义。还提供了制备式(I)化合物的方法,含有式(I)化合物的药物组合物和试剂盒,以及治疗子宫内膜异位症、激素依赖性癌症、平滑肌瘤、子宫肌瘤、功能性出血、多囊卵巢综合征和与更年期相关症状的方法;避孕方法;提供激素替代疗法的方法;促进食欲的方法;同步发情的方法;以及通过向需要的哺乳动物施用式(I)化合物的药学有效量来治疗经前综合征和经前期情感障碍症状的方法。
  • [EN] CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS<br/>[FR] DERIVES DE CYCLOTHIOCARBAMATE TENANT LIEU DE MODULATEURS DU RECEPTEUR DE PROGESTERONE
    申请人:AMERICAN HOME PROD
    公开号:WO2000066570A1
    公开(公告)日:2000-11-09
    The present invention provides compounds which are agonists of the progesterone receptor and have structures (I) or (II) wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR?A or NRBCORA; or R1 and R2¿ are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; RA is selected from H, amino, or optionally substituted C¿1? to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; R?B¿ is H, C¿1? to C3 alkyl, or substituted C1 to C3 alkyl; R?3¿ is H, OH, NH¿2 COR?C, or optionally substituted C¿1? to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; R?C¿ is selected from H or optionally substituted C¿1? to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; Q?1¿ is S, NR?7; or CR8R9, R5¿ is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO¿2? or NR?6¿; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.
    本发明提供了具有结构(I)或(II)的孕激素受体激动剂化合物,其中R1和R2是独立的取代基,选自H,可选取代的C1至C6烷基,烯基,炔基或C3至C8环烷基,芳基,取代芳基或杂环基,或COR?A或NRBCORA; 或R1和R2¿融合形成可选取代的3至8环螺环烷基或烯基环或含有1至3个杂原子(选自O,S和N)的螺环状环;RA选自H,基或可选取代的C¿1?至C3烷基,芳基,C1至C3烷氧基或C1至C3基烷基基团;R?B¿选自H,C¿1?至C3烷基或取代的C1至C3烷基;R?3¿选自H,OH,NH¿2 COR?C,或可选取代的C¿1?至C6烷基,C3至C6烯基或炔基基团;R?C¿选自H或可选取代的C¿1?至C3烷基,芳基,C1至C3烷氧基或C1至C3基烷基基团;Q?1¿选自S,NR?7; 或CR8R9,R5¿为可选的三取代苯环或带有1、2或3个选自O,S,SO,SO¿2?或NR?6¿的杂环的可选取代的五元或六元环;或其药学上可接受的盐,以及使用这些化合物进行避孕和治疗孕激素相关疾病的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫